Mark Newman is recorded as COO at Chemours Co (CC). The newest filing on record that lists Mark Newman as COO at Chemours Co (CC) is dated March 12, 2021. Chemours Co reported in an 8-K filed March 25, 2024 that Mark Newman resigned as director, effective March 22, 2024. Chemours Co reported in an 8-K filed March 25, 2024 that Mark Newman resigned as President and Chief Executive Officer, effective March 22, 2024. The proxy statement of GeoVax Labs, Inc. reports total compensation of $291,500 for Mark Newman in fiscal 2023, including a base salary of $291,500. Disclosed compensation is on record for 5 fiscal years. Mark Newman has spoken on 16 earnings calls across 2 companies, most recently for GeoVax Labs, Inc. on November 13, 2024. Those appearances were for Chemours Co (CC) and GeoVax Labs, Inc. (GOVX). Chemours Co is classified in the Specialty Chemicals industry within the Basic Materials sector. GeoVax Labs, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Chemours Co includes Mark E. Newman (CEO and Board Member), Mark Vergnano (CEO and Chairman), Jonathan Lock (CFO) and 7 others.
“Ms. Dignam succeeds Mark Newman, who resigned from his officer and director positions with the Company, also effective as of March 22, 2024.”
Chemours Co Form 8-K, filed March 25, 2024
· Read the filing
“Ms. Dignam succeeds Mark Newman, who resigned from his officer and director positions with the Company, also effective as of March 22, 2024.”
Chemours Co Form 8-K, filed March 25, 2024
· Read the filing
Mark Newman on recent calls
“So there’s a pretty standard process evaluation that we would go through. So, process development, and I mean that’s well-defined to the regulatory agencies. The key element will be purifying the virus to standards that are acceptable by the FDA.”
“You know, 2023 has been a challenging year with a weaker second half than we expected. But The Chemours team remains focused on driving long-term shareholder value and improvements in our three industry-leading businesses.”
“In addition to reporting solid results in the second quarter, as you saw from our press release, we had an active and productive quarter. In TSS, we had another all-time record quarter.”
“Our strong performance in the first quarter is a testament to our secular growth thesis at work and the strength of our overall portfolio. TSS and APM continue to deliver products the world needs and which underpin many strategic as well as emerging technologies.”
“The mRNA is a platform, as you mentioned, where it really enables you to do a rapid response. So there's a difference between a response and building a vaccine capability.”
